UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-04, Vol.374 (17), p.1621-1634

2016

Volltextzugriff (PDF)

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Journal of hematology and oncology, 2018-01, Vol.11 (1), p.10-10, Article 10

2018

Volltextzugriff (PDF)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

Leukemia, 2014-01, Vol.28 (1), p.210-212

2014

Volltextzugriff (PDF)

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry

British journal of haematology, 2024-09, Vol.205 (3), p.990-998

2024

Volltextzugriff (PDF)

Résultats préliminaires de l’étude exploratoire de phase 2 utilisant la TEP au 68GaPentixaFor pour le bilan initial des patients atteints de myélome multiple (MM) symptomatiques

Médecine nucléaire : imagerie fonctionelle et métabolique, 2023-03, Vol.47 (2), p.50-50

2023

Volltextzugriff (PDF)

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

Annals of oncology, 2016-02, Vol.27 (2), p.314-318

2016

Volltextzugriff (PDF)

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies

Médecine et Maladies Infectieuses Formation, 2024-06, Vol.3 (2), p.S74-S75

2024

Volltextzugriff (PDF)

Résultats préliminaires de l’étude MyelofludaTEP évaluant la TEP à la [18F]Fludarabine pour le bilan initial et l’évaluation thérapeutique du myélome multiple

Médecine nucléaire : imagerie fonctionelle et métabolique, 2024-03, Vol.48 (2), p.47-48

2024

Volltextzugriff (PDF)

Facteurs pronostiques des cryoglobulinémies à composante monoclonale primitives

La revue de medecine interne, 2021-12, Vol.42, p.A282-A282

2021

Volltextzugriff (PDF)

Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma

Bone marrow transplantation (Basingstoke), 2016-08, Vol.51 (8), p.1143-1145

2016

Volltextzugriff (PDF)

B04 IMPLEMENTING M‐PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA‐SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF‐THE‐SHELF CALIBRATOR

HemaSphere, 2023-05, Vol.7 (S2), p.6-6

2023

Volltextzugriff (PDF)

P10 AN ULTRA‐SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M‐PROTEIN IN PERIPHERAL BLOOD (M‐INSIGHT)

HemaSphere, 2023-05, Vol.7 (S2), p.15-15

2023

Volltextzugriff (PDF)

Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier

Bone marrow transplantation (Basingstoke), 2017-07, Vol.52 (7), p.1063-1064

2017

Volltextzugriff (PDF)

P30 SINGLE COHORT RESULTS FROM MAJESTEC‐2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

HemaSphere, 2023-05, Vol.7 (S2), p.27-27

2023

Volltextzugriff (PDF)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH‐RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018‐04

HemaSphere, 2022-06, Vol.6, p.77-78

2022

Volltextzugriff (PDF)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

HemaSphere, 2023-05, Vol.7 (S2), p.26-27

2023

Volltextzugriff (PDF)

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

Annals of hematology, 2017-06, Vol.96 (6), p.943-950

2017

Volltextzugriff (PDF)

P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I‐DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018‐02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM)

HemaSphere, 2022-06, Vol.6 (Suppl), p.819-820

2022

Volltextzugriff (PDF)

Gammapathies monoclonales de signification indéterminée

EMC - Hématologie, 2012-05, Vol.7 (2), p.1-6

2012

Volltextzugriff (PDF)

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-04, Vol.374 (17), p.1621-1634

2016

Volltextzugriff (PDF)

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B‐CELL MATURATION ANTIGEN (BCMA)‐TARGETED AGENTS

HemaSphere, 2022-06, Vol.6, p.85-86

2022

Volltextzugriff (PDF)

Prédiction de la progression chez des patients atteints de myélome multiple avec des Random Survival Forest

Médecine nucléaire : imagerie fonctionelle et métabolique, 2019-03, Vol.43 (2), p.193-193

2019

Volltextzugriff (PDF)

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH‐RISK CYTOGENETICS. IFM 2014‐01

HemaSphere, 2022-06, Vol.6 (Suppl), p.783-784

2022

Volltextzugriff (PDF)

Multiple myeloma imaging

Diagnostic and interventional imaging, 2013-02, Vol.94 (2), p.190-192

2013

Volltextzugriff (PDF)

1 – 25 von 399

Suche als RSS-Feed

Aktive Filter

ThemaCancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(342)
Mit Volltextzugriff
(263)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry

Résultats préliminaires de l’étude exploratoire de phase 2 utilisant la TEP au 68GaPentixaFor pour le bilan initial des patients atteints de myélome multiple (MM) symptomatiques

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies

Résultats préliminaires de l’étude MyelofludaTEP évaluant la TEP à la [18F]Fludarabine pour le bilan initial et l’évaluation thérapeutique du myélome multiple

Facteurs pronostiques des cryoglobulinémies à composante monoclonale primitives

Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma

B04 IMPLEMENTING M‐PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA‐SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF‐THE‐SHELF CALIBRATOR

P10 AN ULTRA‐SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M‐PROTEIN IN PERIPHERAL BLOOD (M‐INSIGHT)

Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier

P30 SINGLE COHORT RESULTS FROM MAJESTEC‐2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH‐RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018‐04

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I‐DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018‐02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM)

Gammapathies monoclonales de signification indéterminée

P42 HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL‐1

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B‐CELL MATURATION ANTIGEN (BCMA)‐TARGETED AGENTS

Prédiction de la progression chez des patients atteints de myélome multiple avec des Random Survival Forest

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH‐RISK CYTOGENETICS. IFM 2014‐01

Multiple myeloma imaging

Aktive Filter

Suchergebnisse filtern